Çalışma Alanları
- Sağlık Bilimleri Temel Alanı
- Tıbbi Onkoloji (İç Hastalıkları)
- BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers, 2023
- PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score, 2023
- Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study, 2023
- Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study, 2023
- Classifying Invasive Lobular Carcinoma as Special Type Breast Cancer May Be Reducing Its Treatment Success: A comparison of Survival Among Invasive Lobular Carcinoma, Invasive Ductal Carcinoma, and No-Lobular Special Type Breast Cancer, 2023
- External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database, 2023
- An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea, 2023
- Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series, 2022
- The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study, 2022
- Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib, 2022
- Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade, 2022
- Prognostic Factors for Survival in Transverse Colon Cancers, 2022
- ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences, 2022
- Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey, 2022
- Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS), 2022
- Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry, 2022
- An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction, 2022
- Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide, 2022
- Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series, 2022
- Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma, 2022
- Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma, 2022
- Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma, 2022
- Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies, 2022
- Investigation of The Relationship of <i>TNFRSF11A</i> Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with <i>BRCA1</i> Or <i>BRCA2</i> Pathogenic Variants Living in The Trakya Region of Turkey., 2021
- Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study, 2021
- Merkel cell carcinoma in Turkey: A multicentric study, 2021
- Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity, 2021
- Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?, 2021
- Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer., 2021
- Clinicopathological and prognostic characteristics of acral metastases in patients with malignant disease: A retrospective study, 2021
- Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival., 2021
- Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study, 2021
- Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study, 2021
- A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer, 2021
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, 2021
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non\u2013Small Cell Lung Cancer, 2021
- Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective, 2021
- Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience, 2021
- The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment, 2021
- Need for Patient Education and Better Physician-Patient Communication in Melanoma Patients, 2021
- The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer, 2020
- Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer, 2020
- Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Efficacy of regorafenib in the second-and third-line settingfor patients with advanced hepatocellular carcinoma: A reallife data of multicenter study from Turkey, 2020
- Efficacy of Regorafenib in the Second-and Third-line Settingfor Patients with Advanced Hepatocellular Carcinoma: A RealLife Data of Multicenter Study from Turkey, 2020
- GLASS: Global Lorlatinib for ALK() and ROS1() retrospective Study: real world data of 123 NSCLC patients, 2020
- Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak, 2020
- Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn’s disease: A case report, 2020
- Prognostic Effect of Albumin-Bilirubin Grade on Survival in Advance Gastric Cancer Patients with de-novo Liver Metastasis, 2020
- Comparison of Neoadjuvant Chemotherapy and Bladder-Preserving Chemoradiation in Patients with Non-Metastatic, Muscle-Invasive Bladder Cancer: A Single-Center Experience, 2020
- Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study, 2020
- Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study, 2020
- Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey, 2020
- Genetic screening results of individuals with high risk BRCArelated breast/ovarian cancer in Trakya region of Turkey, 2020
- The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas, 2020
- GLASS: Global Lorlatinib for ALK() and ROS1() retrospective Study: real world data of 123 NSCLC patients, 2020
- Evaluating Sun Protection Behaviors and Skin Self Examination Practices Among the Family Members of Melanoma Patients in Turkey: A Cross-sectional Survey Study, 2020
- Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer, 2020
- Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study, 2020
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial, 2020
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE), 2020
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407, 2020
- Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis, 2020
- Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study, 2020
- Concordance of PD-L1 expression and CD8 TIL intensity between NSCLC and synchronous brain metastases, 2020
- Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey, 2020
- The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas, 2020
- Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study, 2020
- Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer, 2020
- Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102, 2019
- Regorafenib or rechallenge chemotherapy: Which is more effective in the third-line treatment of metastatic colorectal cancer?, 2019
- Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases, 2019
- Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?, 2019
- Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer, 2019
- Comparison of skeletal muscle mass loss in patients withmetastatic colorectal cancer treated with regorafenib orTAS-102, 2019
- Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib, 2019
- Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib, 2019
- The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer, 2019
- Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP), 2019
- Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer, 2019
- Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases, 2019
- The albumin-bilirubin (ALBI) grade as a significant prognostic factor in colorectal cancer patients with liver metastases, 2019
- Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma, 2018
- Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes, 2018
- Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA), 2018
- Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma, 2018
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, 2018
- Clinical Features of the Patient with Multiple Primary Tumors: Single Center Experience, 2017
- K-RAS and N-RAS mutations in testicular germ cell tumors, 2017
- Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis., 2017
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial, 2017
- KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer, 2016
- Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment, 2016
- Endometrial carcinoma and paraneoplastic immune thrombocytopenia, 2016
- Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report, 2016
- Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor EGFR mutation, 2016
- Endometrial carcinoma and paraneoplastic immune thrombocytopenia, 2016
- Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second line treatment, 2016
- Metastatik Küçük Hücreli Dışı Akciğer Kanserinde Kaç Seri Kemoterapi Verilmeli, 2016
- Biyobenzer Ürünlerde Klinik Uygulamada Karşılaşılabilecek Sorunlar, 2016
- Unknown primary adenocarcinomas a single center experience, 2016
- The effect of the gastrectomy on survival in patients with metastatic gastric cancer a study of ASMO, 2016
- A rare cause in etiology of left atrial mass metastatic testicular germ cell tumor, 2016
- Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas, 2016
- Unknown primary adenocarcinomas a single center experience, 2016
- Modified docetaxel cisplatin and fluorouracil therapy as the first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study, 2016
- Single agent bevacizumab is an effective treatment in recurrent glioblastoma, 2015
- Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer, 2015
- Comparative analysis of the efficacy and safety of modified FOLFOX 6 and DCF regimens as first line treatment in advanced gastric cancer, 2015
- Increased dose single agent gemcitabine in platinum taxane resistant metastatic ovarian cancer, 2015
- Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5 Fluorouracil Leucovorin Modified FOLFOX6 with Advanced Gastric Cancer Patients having a Good or Poor Performance Status, 2015
- Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors, 2015
- Importance of Ki 67 in human epidermal growth factorreceptor 2 positive breast cancer, 2015
- Denosumab a Monoclonal Antibody not a Radionuclide, 2015
- Incidence of contrast induced nephropathy in hospitalised patients with cancer, 2014
- Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors, 2014
- Incidence of contrast induced nephropathy in hospitalised patients with cancer, 2014
- Incidence of contrast induced nephropathy in hospitalised patients with cancer, 2014
- Medical Treatment of Breast Cancer Bone Metastasis From Bisphosphonates to Targeted Drugs, 2014
- Performance Status is an Important Prognostic Factor in Second Line Treatment of Pancreaticobiliary Adenocarcinoma, 2013
- Assessment of CA 125 area under the curve as a prognostic factor in patients with ovarian cancer, 2013
- Carnitine or dimethyl sulfoxide or both for the treatment of anthracycline extravasation in rats, 2013
- Protective effect of l carnitine versus amifostine against cisplatin induced nephrotoxicity in rats, 2011
- Inflammatory myofibroblastic tumor presenting as an abdominal wall mass in an adult patient, 2010
- Implantation of central venous ports with chest catheter insertion via the subclavian vein in oncology patients In single center experience, 2009
- Massive Upper Gastrointestinal Bleeding From Pure Metastatic Choriocarcinoma in Patient With Mixed Germ Cell Tumor With Subclinical Intestinal Metastasis, 2009
- Extrapulmonary small cell carcinoma localized in lymph nodes Is it a different clinical entity, 2009
- The effect of Saccharomyces boulardii on reducing irinotecan induced intestinal mucositis and diarrhea, 2009
- Triple negative breast cancer compared to hormone receptor negative HER2 positive breast cancer, 2009
- Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis, 2009
- The comparison of weekly and three weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non metastatic squamous cell carcinoma of the head and neck, 2009
- Malignant Ovarian Germ Cell Tumors, 2009
- Synchronous Tonsil Gallbladder and Cardiac Metastases without any other Visceral Metastases of Malignant Melanoma, 2009
- Yolk sac tumours of the ovary Evaluation of clinicopathological features and prognostic factors, 2009
- Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI bevacizumab, 2009
- A Case of Malignant Melanoma With Cardiac and Gallbladder Metastases Detected by FDG PET CT, 2009
- Pleomorphic liposarcoma of the pectoralis major muscle in an elderly man Report of a case and review of literature, 2009
- Effect of maximum tolerated doses and low dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin 1 levels in patients with advanced nonsmall cell lung cancer, 2008
- The efficiency of single agent docetaxel in patients with platinum refractory non small cell lung carcinoma, 2008
- Ovarian carcinosarcomas Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum, 2008
- Effect of maximum tolerated doses and low dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin 1 levels in patients with advanced nonsmall cell lung cancer, 2008
- Factors affecting the prognosis of breast cancer patients with brain metastases, 2008
- Extrapulmonary small cell carcinoma compared with small cell lung carcinoma, 2007
- Efficient and Safe Application of a FOLFIRI Bevacizumab Combination to a Patient with Locally Advanced Rectal Cancer and Severe Chronic Renal Failure, 2007
- Colonic Metastasis from Carcinoma of the Breast that Mimics a Primary Intestinal Cancer, 2006
- Colonic Metastasis from Carcinoma of the Breast that Mimicks a Primary Intestinal Cancer, 2006
- Isolated Bone Metastasis in Testicular Germ Cell Tumors A Case Report and Review of the Literature, 2006
- Fatal hepatic veno-occlusive disease in an adult patient with Wilms’xx tumour., 2003
- Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma Case report,
- EFFICACY AND SAFETY OF FOLFIRI/AFLIBERCEPT IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS (TOG STUDY) , 2020
- MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer, 2022
- LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829), 2022
- LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial, 2022
- Crizotinib efficacy in ALK-positive advanced stage non-small cell lung cancer patients: a real-world experience from Turkey., 2018
- Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wi̇ld-type patients treated with biologics second-line mCRC., 2022
- Geriatrik (≥75 Yaş), Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Hastalarında 1. Basamak Anti- Androjen Tedavi Sonuçları- Gerçek Yaşam Verisi, 2019
- Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçlari- Gerçek Yaşam Verisi, 2019
- PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY), 2020
- Efficacy of crizotinib in patients with ALK positive advanced stage non-small cell lung cancer: A real-world experience from Turkey, 2018
- Is there any prognostic significance in pleural involvement and/oreffusion (Ple-I/E) in patients with ALK-positive NSCLC?, 2019
- PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY), 2020
- Evre 4 Akciğer Adenokarsinomlu 1081 Hastanın NGS (Next GenerationSequencing) Verileri, 2020
- Birinci Basamak İmmünoterapi Alan Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Yanıt Derinliği ile Yanıt Dayanıklılığı ve Genel Sağkalım İlişkisi, 2020
- Association of The Role of Cytochrome P4501a1 Gene Polymorphism In Colorectal Cancer, 2015
- EFFICACY AND SAFETY OF FOLFIRI/AFLIBERCEPTIN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS (TOG STUDY), 2020
- İLERİ EVRE KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE ANJİYOGENİK ANTİANJİYOGENİK DENGENİN SAĞKALIM SÜRELERİNE ETKİSİ,
- Association Of Glutatyon S Transferaz M1 Gene Polimorphism Genotypes And Serum Iron Levels In Colorectal Cancer, 2015
- Investigation of GSTM1 polymorphism genotypes and serum trace elements in colorectal cancer, 2015
- Kolorektal Kanserli Hastalarda Sitokrom P4501A1 (rs:1048943) Gen Polimorfizminin Araştırılması, 2017
- Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA)., 2017
- Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wi̇ld-type patients treated with biologics first-line metastatic colorectal cancer, 2021
- LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%, 2020
- PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY) Cihan Erol1 , Mutlu Hızal2 , Irem Bilgetekin3 , Sinem Akbas4 , Duygu Bayir Garbioglu5 , Jamshid Hamdard6 , Cagatay Arslan7 , Alper Sevinc8 , Ahmet Kucukarda9 , Dilek Gurgenyatagi10, Emre Cakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, Izzet Dogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17, Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut Emre Yildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, Halil Taskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25, Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, Abdullah Sakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1 , Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, Semra Paydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9 , Ahmet Bilici6 , Didem Sener Dede1 , Muhammed Bulent Akinci1 , Nil Molinas Mandel36, Berna Oksuzoglu3 , Dogan Uncu2 , Bulent Yalcin1 , Mehmet Artac12, Mehmet Ali Nahit Sendur1, 2020
- KANSER HASTALARINDA KONTRASTLI BİLGİSAYARLITOMOGRAFİ ÇEKİMİ SONRASI KONTRAST MADDENEFROPATİSİ GELİŞME RİSKİ VE PREDİKTİF FAKTÖRLER, 2012
- The Efficacy and Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC: The Real-world Experience from Turkey, 2018
- Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC), 2019
- Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged = 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS, 2019
- P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey, 2019
- 1547 P: Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?, 2019
- Real-world assessment of clinical effectiveness and safety ofpazopanib in patients with advanced or metastatic renal cellcarcinoma (RCC) in Asia, North Africa and Middle East countries: Aprospective, observational study (PARACHUTE), 2019
- Real-world assessment of clinical effectiveness and safety ofpazopanib in patients with advanced or metastatic renal cellcarcinoma (RCC) in Asia, North Africa and Middle East countries: Aprospective, observational study (PARACHUTE), 2019
- Real-world assessment of clinical effectiveness and safety ofpazopanib in patients with advanced or metastatic renal cellcarcinoma (RCC) in Asia, North Africa and Middle East countries: Aprospective, observational study (PARACHUTE), 2019
- Real-world assessment of clinical effectiveness and safety ofpazopanib in patients with advanced or metastatic renal cellcarcinoma (RCC) in Asia, North Africa and Middle East countries: Aprospective, observational study (PARACHUTE), 2019
- Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?,
- Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi, 2019
- CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY, 2018
- The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey, 2018
- Assessment of Tumor Response, AFP Response, and Time to Progression in the Phase 3 CELESTIAL Trial of Cabozantinib Versus Placebo in Advanced Hepatocellular Carcinoma, 2018
- Health-Related Quality of Life (HRQoL) for Pembrolizumab or Placebo Plus Carboplatin and Paclitaxel or Nab-paclitaxel in Patients With Metastatic Squamous NSCLC: Data From KEYNOTE-407, 2018
- Choice of Taxane and Outcomes in the KEYNOTE-407Study of Pembrolizumab Plus Chemotherapy forMetastatic Squamous NSCLC, 2018
- Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial., 2018
- Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results, 2018
- The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey., 2018
- Crizotinib Efficacy in ALK-Positive Advanced StageNon-Small Cell Lung Cancer Patients: A Real-WorldExperience from Turkey, 2018
- Does the PD-L1 Status and TIL Intensity Change in NSCLC and Syncronous Brain Metastases? P2.02-073a, 2017
- Acase Of Treatment And Patient Endometriım Canser Nursing Care, 2012
- Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial., 2018
- P1. 01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey, 2018
- Crizotinib Efficacy in ALK-Positive Advanced StageNon-Small Cell Lung Cancer Patients: A Real-WorldExperience from Turkey,
- Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)., 2018
- Pankreas kanserinin postoperatif tedavisi: Retrospektif değerlendirme,
- Screening for germline variations of cancer related genes in patients with the diagnosis of different cancers and hereditary cancer predisposition syndromes, 2018
- An open-label, Multinational, Phase IIIb Study to Evaluate Patient andSatisfaction, Safety and Efficacy of Subcutaneous Administration ofTrastuzumab in Patients With HER2-Positive Early Breast Cancer(ML28851) in Adjuvant/Neo-Adjuvant Setting, 2018
- Characteristics of Turkish colorectal cancer patients and bevacizumab preference., 2017
- Outcomes of Turkish National Breast Cancer Registry., 2017
- Outcomes of Turkish National Breast Cancer Registry,
- Yeni Nesil Klinik Çalışmalar,
- Türkiye’de Faz Çalışmaları,
- Characteristics of Turkish colorectal cancer patients and bevacizumab preference, 2017
- Outcomes of Turkish National Breast Cancer Registry., 2017
- EFFECTIVENESS AND SAFETY OF LMWH TREATMENT IN CANCER PATIENTS DIAGNOSED WITH NON-HIGH RISK VENOUS THROMBOEMBOLISM (VTE) - RESULTS OF TURKISH OBSERVATIONAL STUDY (TREBECA),
- Sınırlı evre küçük hücreli akciğer kanserinde kemoradyoterapi sonuçları, 2012
- Onkoloji hastalarında göğüs duvarı yerleşimli santral venöz kateter uygulamaları tek merkez deneyimi,
- Turkish National Breast Cancer Registry, 2015
- Karşılaştırılamayan biyolojik ajanlar Ne biliyoruz,
- Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer mCRC Long term safety observation from the global aflibercept safety and quality of life QoL program ASQoP,
- KANSER HASTALARINDA KONTRASTLI BiLGiSAYARLITOMOGRAFi ÇEKİMİ SONRASI KONTRAST MADDENEFROPATiSi GELİŞME RiSKi VE PREDİKTiFFAKTORLER ÇALIŞMASI FiNAL SONUCLARI, 2014
- REKÜRREN GLİOBLASTOMA TEDAVİSİNDE TEK AJAN BEVACİZUMAB, 2014
- Mide karsinomlarında sitokin ve epidermal büyüme faktörü EGFR düzeyleri, 2011
- Memenin Primer Nöroendokrin Tümörü,
- The Relationship between Selenium Levels and Genotypes of the Cytochrome P450 1A1 Gene Polymorphisms in Colorectal Cancer, 2015
- Low molecular weight heparin LMWH treatment in cancer patients with low risk venous thromboembolism results of Turkish Observational Study TREBECA, 2015
- Low molecular weight heparin LMWH treatment in cancer patients with low risk venous thromboembolism results of Turkish Observational Study TREBECA, 2015
- Effect of body mass index in gastric cancer patients Analysis of Turkish national gastric cancer registry, 2015
- Turkish National Breast Cancer Registry, 2015
- Turkish National Colon Cancer Registry, 2015
- Turkish National Gastric Cancer Registry, 2015
- Erken evre meme kanserinde primer KT mi primer cerrahi mi,
- Orijinal Biyolojik Ürün veya Biyobenzer Ürünle Yapılan Klinik Çalışmalar Farklı mıdır Hedef Kanser 2015 02 Nisan 20015,
- Meme Kanseri sözel bildiri tartışmacılığı tedavi konuşmacı 22 26 Nisan 2015 Antalya,
- Kolon Kanseri Adjuvan Tedavisinde Farmakogenomik veriler ilerisi için umut olabilir mi konuşmacı 14 Mart 2015 Çeşme,
- Biyobenzerler konuşmacı,
- Trakya Bölgesi ndeki Kolorektal Kanserli Hastalarda Glutatyon S Transferaz Gen Polimorfizminin Araştırılması, 2015
- Aktif Sigara İçiciliği EGFR Mutant Akciğer Adenokanseri Hastalarında Kötü Bir Prognostik Faktördür,
- Parotis Bezi Metastazı ile Tanı Alan Akciğer Kanseri Olgusu,
- Kontrastlı Bilgisayarlı Tomografi Çekimi Sonrası Kontrast Madde Nefropatisi Gelişme Riski Ve Prediktif Faktörler,
- HR pozitif HER2 negatif meme kanserinde tedaviler ve güncel yakşaımlar, ISBN: 978-625-401-536-6, 2022
- Clinical Research at MENA, Challenges and Solutions, ISBN: 9783631863855, 2022
- Geriatrik Onkoloji, ISBN: 978-625-401-191-7, 2020
- Prostat Kanseri Yönetimi, ISBN: 978-605-06114-4-1, 2020
- Son Dönem Kanser Hastasında Nütrisyonel Tedavi, ISBN: 978-625-401-045-3, 2020
- KANSER VE COVID-19 PANDEMİSİ, ISBN: 978-625-401-049-1, 2020
- İmmunoterapilerde Yan Etki Yönetimi, ISBN: 978-605-7650-02-3, 2019
- İmmünoterapilerde Yan Etki Yönetimi, ISBN: 978-605-7650-02-3, 2019
- Biyoteknolojik İlaçlar, ISBN: 978-625-400-344-8, 2020
- Biyoteknolojik İlaçlar, ISBN: 978-625-400-344-8, 2020
- Biyoteknolojik İlaçlar, ISBN: 978-625-400-344-8, 2020
- Biyoteknolojik İlaçlar, ISBN: 978-625-400-344-8, 2020
- Breast Cancer, A Guide to Clinical Practice, ISBN: 978-3-319-96947-9, 2019
- Textbook of Gastrointestinal Oncology, ISBN: 978-3-030-18890-0, 2019
- Breast DiseaseManagement and Therapies, ISBN: 978-3-030-16792-9, 2019
- Breast Cancer A Guide to Clinical Practice, ISBN: 978-3-030-16792-9, 2019
- İleri Evre Mide Kanserinde Tedavi Yaklaşımlar, ISBN: 978-975-9118-71-6, 2018
- GEBELİKTE SARKOM TEDAVİSİ, ISBN: 978-975-277-675-3, 2017
- Gebelikte Kanser Tedavisi, ISBN: 978-975-277-675-3, 2017
- İLERİ EVREKÜÇÜK HÜCRELİ DIŞIAKCİĞER KANSERİTANI VE TEDAVİ KILAVUZU, ISBN: , 2017
- Sorularla Biyoteknoloji ve Biyobenzer İlaçlar Editor irfan Çİçin,, ISBN: 978-975-277-697-5, 2017
- Breast Disease, ISBN: 978-3-319-26010-5, 2016
- Uygun K ve İ Çiçin Meme Kanserleri ed K Engin 433 442 Nobel Tıp Kitabevleri Bursa 2005, ISBN: , 2005
- Harrison İç Hastalıkları Prensipleri 15 Baskı, ISBN: , 2004
- Harrison İç Hastalıkları Prensipleri 15 Baskı, ISBN: , 2004
- Yönelik Tedavilerin Yan Etkileri ve Yan Etkilerin Yönetimi, ISBN: , 2014
- Yönelik Tedavilerin Yan Etkileri ve Yan Etkilerin Yönetimi, ISBN: , 2014
- Yönelik Tedavilerin Yan Etkileri ve Yan Etkilerin Yönetimi, ISBN: , 2014
